Providence Medical Chooses Former NuVasive Manager for CCO Job

Providence Medical Technology Inc. has welcomed a new member to its C-Suite, recruiting industry veteran Jim Hens as chief commercial officer.

With more than 25 years of leadership experience in the orthopedic and spine industries, Hens was hired to spearhead the company’s commercial expansion and continue its growth. He brings a proven track record of scaling medical device organizations, most recently as U.S. managing director for Silony Spine, where he administered all U.S. operations. Before that, he was a general manager at NuVasive Inc. (acquired by Globus Medical Inc. in 2023), where he managed its largest division for three years, achieving record growth.

Hens’ appointment occurs as Providence extends its rapid growth, fueled by its landmark 202-patient FUSE study, which was published in the journal Spine. The prospective, randomized controlled trial is the first study of its kind and demonstrates that multi-level circumferential cervical fusion (CCF)—the fusion of all spinal segment joints—delivered clinically superior outcomes when compared to the more commonly performed anterior cervical discectomy and fusion (ACDF).¹ 

“I am thrilled to join Providence,” Hens stated. “The data from the FUSE study is a watershed moment for the industry, proving that we can significantly reduce surgical failures through a tissue-sparing, circumferential approach. I look forward to leading this team to ensure surgeons have the instruments, implants, and support they need to achieve higher rates of fusion success for their patients.”

In 2025, the company achieved key milestones to accelerate growth, including expanding its direct sales force, successfully launching its PCSS product line, and introducing a line of lumbar navigational compatible products to bring CORUS technology to lumbar spinal fusions. The company’s focus on delivering proven patient outcomes through rigorous clinical research and truly differentiated product designs has driven 40% revenue growth in 2024 and 2025, according to company bigwigs. In addition, Providence’s unique business model delivered two consecutive years of positive Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) while investing significantly in clinical trials, new product innovation, and rapid expansion of its direct sales force.

“The company is at an exciting inflection point where Providence’s clinical evidence is accelerating market demand,” Providence Chief Product Officer Scott Lynch said. “Jim is a rare talent who combines deep operational expertise and spine industry knowledge with a visionary approach to sales leadership. His skill in successfully leading high-performance teams will be critical as we leverage the clinical superiority of our CORUS technology to make CCF the standard of care for cervical spine fusion patients, and in growing CORUS technology adoption in lumbar spine fusion patients.”

Providence Medical Technology Inc. is a privately held medical device company based in Pleasanton, Calif. The company strives to improve clinical outcomes for spinal fusion patients and prevent surgical failures through its tissue-sparing, clinically proven solutions, including its CORUS technology.

Reference
¹ Strenge KB, et al. Three-Level Anterior Cervical Discectomy and Fusion With or Without an Investigational Posterior Stabilization System Assessed Through 24 Months: A Multicenter Randomized Controlled Trial. Spine (Phila Pa 1976). 2025 Sep 1;50(17):1161-1170. PMID: 40331720.